Hennion & Walsh Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Hennion & Walsh Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-26,066	Closed	-$1.26M	–	944
2025 Q1	$1.26M	Sell	26,066 -6,008	-19%	-$252K	0.06%	416
2024 Q4	$1.24M	Sell	32,074 -5,339	-14%	-$233K	0.06%	413
2024 Q3	$1.68M	Sell	37,413 -467	-1%	-$18.9K	0.08%	321
2024 Q2	$1.31M	Buy	37,880 +2,985	+9%	+$87.4K	0.07%	362
2024 Q1	$1.01M	Buy	34,895 +849	+2%	+$23.1K	0.05%	420
2023 Q4	$781K	Buy	34,046 +2,380	+8%	+$41.6K	0.04%	468
2023 Q3	$528K	Buy	31,666 +14,958	+90%	+$290K	0.03%	503
2023 Q2	$461K	Buy	+16,708	New	+$418K	0.03%	532

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hennion & Walsh Asset Management's PTGX Position: Q2 2025 in Review

Hennion & Walsh Asset Management sold out of Protagonist Therapeutics (PTGX) in Q2 2025, closing a stake of 26,066 shares — an estimated $1.26M sold.

Hennion & Walsh Asset Management first reported a position in PTGX in Q2 2023 and held it in 8 quarters. The position peaked at $1.68M in Q3 2024. 272 funds tracked by Wall St. Rank hold PTGX as of Q2 2025.

Hennion & Walsh Asset Management reported no remaining Protagonist Therapeutics position as of Q2 2025 after selling out during the quarter.
Hennion & Walsh Asset Management sold 26,066 Protagonist Therapeutics shares in Q2 2025, an estimated $1.26M.
Hennion & Walsh Asset Management first reported a position in Protagonist Therapeutics in Q2 2023 and held it in 8 quarters.
Hennion & Walsh Asset Management's Protagonist Therapeutics position peaked at $1.68M in Q3 2024.
272 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2025.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2025, filed 7 Aug 2025.